 Context Therapeutics NASDAQ:CNTX Inc announced what it called encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release ONA-XR, the companys lead clinical program. Context said the lead clinical-stage oral progesterone receptor PR antagonist ONA-XR demonstrated strong efficacy across multiple PR solid tumor models. 